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Abstract
Background-There is some controversy
concerning the efficacy of low dose a
interferon therapy in chronic hepatitis C.
Aims-To evaluate the effectiveness of
treatment with low doses ofa interferon in
chronic hepatitis C.
Patients-One hundred and forty one
patients with anti-HCV positive chronic
active hepatitis C from six hospitals were
enrolled in the study.
Methods-Patients were randomised to
treatment with 5 MU (group A) or 1-5 MU
(group B) injections. The dose was
reduced in responders from group A or
increased in non-responders from group
B to maintain treatment with the miniimal
effective dose. Patients were treated for 48
weeks and followed up for 24 additional
weeks with no treatment. Normalisation
of alanine aminotransferase (ALT) was
used to evaluate response.
Results-A sustained response was seen in
eight patients from group A (12%) and in
15 (21%) from group B. This difference
was not statistically significant. In-
creasing the dose of interferon led to sus-
tained response in only five of 58 patients
(90/o) from group B who did not respond to
1-5 MU injections. In contrast, 15 of 21
patients (71%) in whom ALT remained
normal with 1.5 MU injections developed
a sustained response. By multivariate
analysis sustained response seemed
associated with young age and was more
frequent in patients with genotype 3 HCV
infection. Sustained response was pre-
ceded by a rapid normalisation of ALT
and was inversely related to the amount of
a interferon necessary to maintain ALT at
low values during treatment.
Conclusions-Some patients with chronic
hepatitis C are very sensitive to a inter-
feron and can be successfully treated with
low doses. Treatment with higher doses
may be effective in a minority of patients
who do not respond to low doses.
(Gut 1996; 38: 603-609)
Keywords: hepatitis C therapy, hepatitis C virus,
interferon.
Chronic infection with the hepatitis C virus
(HCV) is the main cause of chronic hepatitis in
Western countries and in Japan.1-3 Chronic
hepatitis C is a serious condition because it
may lead to development of cirrhosis of the
liver and hepatocellular carcinoma.4-7
Administration of ao interferon is currently
accepted as a treatment for chronic hepatitis C
because ao interferon inhibits HCV replication
and induces remission of the activity of the
disease in some cases.8-12 Eradication of the
infection after a interferon therapy has recently
been reported.'3
However, important problems concerning ax
interferon therapy in chronic hepatitis C
remain unsolved. Many patients do not
respond to this treatment and many others
relapse almost immediately after withdrawal of
the treatment. In addition, ax interferon is
expensive and often causes adverse reactions,
which occasionally are serious.14
As most of the unwanted side effects of inter-
feron are dose related,'5 treatment with low
doses might be preferable. However, it is uncer-
tain if low dose interferon therapy is effective in
chronic hepatitis C. In a multicentre study,
Davis et al observed that treatment with 1 MU
per injection three times a week for six months
was less effective than treatment with 3 MU
injections.16 Similar findings arose from two
smaller studies carried out in France.'7 18 In
comparison with lower doses, however, the
advantages of treatment with 3 MU injections
were less clear in a large Italian study'9 and,
recently, Reichen et al showed that treatment
with 15 MU three times a week for 12 months
produced results in the range of those obtained
with higher interferon doses.20 Indeed, treat-
ment with minimal amounts of ax interferon, as
low as 0-25 MU three times a week2' or weekly
6MU injections22 can produce beneficial effects
in some patients.
This multicentre randomised study aimed to
evaluate the effectiveness of low dose inter-
feron therapy in chronic hepatitis C. To this
purpose, a large number of patients were ran-
domised to be treated with decreasing or
increasing doses of interferon depending on
the response to comparatively high (5 MU per
injection) or low (1-5 MU) doses given ini-
tially, respectively.
Methods
PATIENTS
One hundred and forty one consecutive
patients with chronic active hepatitis C partici-
pated in the study. They were recruited in six
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hospitals located in the Barcelona area from
October 1989 to January 1991. Admission
criteria included: (a) increased alanine amino-
transferase (ALT) serum concentrations above
2.5 times the normal value (40 IU/l) on at least
two separate occasions during the six month
period preceding randomisation and (b)
chronic active hepatitis with or without cirrho-
sis confirmed by percutaneous liver biopsy.
Evidence of hepatitis C virus infection was not
a criteria for selection because specific tests
were not universally available at the beginning
of enrolment. Anti-HCV antibodies were posi-
tive, however, in all the cases when tested
retrospectively with a second generation
enzyme linked immunosorbent assay (ELISA)
test (Ortho Diagnostic Systems, Raritan, NJ,
USA).
Patients with current HBV infection (posi-
tive HBsAg), alcohol abuse, autoimmune
hepatitis (presence of antinuclear, antimito-
chondrial, antismooth muscle, or anti-LKM
non-organ specific autoantibodies with a titre
value higher than 1:40), drug induced or meta-
bolic liver disease were not considered for
inclusion. Other exclusion criteria were: age
lower than 18 years or higher than 65 years,
HIV infection, histological diagnosis of chronic
persistent hepatitis or minimal liver lesions,
past or current hepatic decompensation, pre-
vious treatment with antiviral or immuno-
modulatory agents, leucocyte count below
3x 106/1, platelet count below 75x 106/1, preg-
nancy or presence of any significant pathologi-
cal condition other than hepatitis.
Randomisation and treatment schedules
According to histological features, patients
were stratified in three categories: chronic
active hepatitis, chronic active hepatitis with
bridging fibrosis, or bridging necrosis and
chronic active hepatitis with cirrhosis. Patients
from each histological category were ran-
domised to treatment with decreasing doses of
interferon (group A) or with increasing doses
(group B) by computer generated random
numbers.
Group A - interferon aL2b was given by
subcutaneous injection three times per week
during 48 weeks. Treatment was started with 5
MU injections. After 12 weeks oftreatment the
dose of interferon was adjusted according to
individual response. In patients who showed a
decrease of serum ALT greater than 50°/O the
pretreatment values the dose of interferon was
reduced to 3 MU three times a week, which
was given during the next 12 weeks. In patients
with sustained response to 3 MU of interferon
the dose was further reduced to 1.5 MU per
injection for 24 additional weeks. In patients
who had another increase in ALT upon dose
reduction, the previously effective dose was
reintroduced and this dose was maintained
until the end of the treatment period with no
further modification. Treatment was stopped
in patients who did not show a 50O/o decrease
ofALT after 16 weeks of treatment with 5 MU
three times a week.
Group B - interferon was also given three
times a week during 48 weeks. Treatment
started with 1.5 MU injections. This dose was
maintained during the entire treatment period
in patients who achieved a 50% or greater
reduction of ALT. In patients who did not
respond to 1-5 MU injections after eight weeks
of treatment, the dose was increased to 3 MU
three times a week for eight additional weeks.
The dose was then reduced to 1-5 MU or
increased to 5 MU according to response. As
in group A, treatment was maintained with the
minimal effective dose. Treatment was
stopped if a 500/o decrease of ALT did not
occur after 16 weeks of treatment with 5 MU
injections.
Examinations
Complete clinical and biochemical examina-
tion, including liver function tests, serum
glucose, creatinine, blood urea nitrogen, total
protein, albumin, prothrombin time, and full
blood cell count were carried out weekly
during the first month of treatment and at least
every four weeks during the remaining period
of treatment and during the six months follow
up after treatment.
Pretreatment serum samples from all the
patients recruited at one of the participating
centres (Hospital Clinic, Barcelona) were
screened for the presence of specific antibodies
against HCV types 1, 2, and 3. Testing was
performed at the Department of Medical
Microbiology of the University of Edinburgh
with an ELISA test in which synthetic peptides
derived from the NS4 region of the HCV
genome were used as antigen, as described.23
HCV-RNA in serum was examined in serial
serum samples taken at baseline, after 12 and
48 weeks of treatment, and at the end of
post-treatment follow up. Investigation was
performed by polymerase chain reaction
according to Simmonds et al, with minor
modifications.24 In brief, RNA was extracted
from 200 ,ul of serum by the phenol/chloro-
form method25 and reverse transcribed to
cDNA with random primers. cDNA was
amplified by nested polymerase chain reaction
using the two pairs of primers of the 5'UTR of
the HCV genome described by Garson et al.26
TABLE I Pretreatment characteristics ofpatients included
in the study*
Group A Group B
Variable (n= 70) (n= 71)
Age (y) 49 (12) 46 (13)
Sex
males n (/) 39 (56) 41 (58)
females n (/) 31 (44) 30 (42)
Presumed source of infection
blood transfusion n (%) 22 (31) 20 (28)
intravenous drug abuse n (O/o) 2 (3) 9 (13)
unknown n (o/O) 46 (66) 42 (59)
Aspartate aminotransferase (IU/l) 133 (72) 139 (73)
Alanine aminotransferase (IU/l) 236 (146) 272 (177)
y Glutamyltranspeptidase (IU/1) 62 (39) 73 (67)
Platelet count (X 106/l) 174 (51) 179 (63)
White blood cell count (X 106/l) 5-9 (1-9) 6-1 (1-8)
Liver histology
CAH n (%) 33 (47) 37 (52)
CAH with bridging n (/) 28 (40) 24 (34)
CAH with cirrhosis n (%) 9 (13) 10 (14)
*Quantitative data are expressed as mean (standard deviation).
CAH: Chronic active hepatitis.
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TABLE II Relation between interferon dose and response in patients from group A
Total No No Sustained
dose of Response response Relapse response
Interferon dose (MU) cases n (%/°) n (%o) n (%/o) n (%/o)
Maintained at 5 MU* 240 17 0 17 (100) 0 0
Reduced to 3 MU with later increase to 5 MU 648 15 4 (27) 11 (73) 3 (20) 1 (7)
Reduced to 3 MU and to 1-5 MU with later increase to 3 MU 450 21 8 (38) 13 (62) 6 (29) 2 (9)
Reduced to 3 MU and to 1-5 MU 396 17 8 (47) 9 (53) 3 (17) 5 (30)
Total 70 20 (29) 50 (71) 12 (17) 8 (12)
*Treatment was withdrawn in patients who did not respond after 16 weeks of treatment.
Definition of types of response
Response was defined by normalisation of
ALT only when it was sustained until the end
of the treatment period. Depending on events
during follow up after treatment, two cate-
gories of response were defined: sustained
response, defined by normalisation of ALT
persisting until the end of the post-treatment
follow up, and transient response, defined by
normalisation of ALT at the end of treatment
followed by relapse. Lack of normalisation of
ALT at the end of treatment was considered
no response.
Statistical analysis
Quantitative variables were expressed as mean
(SD). The two tailed Student's t test was used
to compare continuous variables between two
groups. Differences between dichotomous
variables were evaluated with x2 analysis or
Fisher's exact test depending on the size of the
sample. A multivariate analysis by stepwise
logistic regression was performed to identify
factors independently associated with
response. Analysis was performed on an inten-
tion to treat basis and all calculations were
made using a SPSS computer program.
The study protocol was approved by the
ethics committee of each participating hospital
and all patients gave their informed consent
prior to randomisation.
Results
Of 141 patients enrolled in the study, 70 were
randomised to receive treatment with decreas-
ing doses of interferon (group A) and 71 to
receive increasing doses of interferon (group
B). The demographic, clinical, biochemical,
and histological features of both groups were
similar (Table I).
Twenty eight patients from each group did
not complete 48 weeks of treatment. In 17
cases in group A and in 18 in group B the treat-
ment was interrupted after 16 weeks at the
highest dose (5 MU three times a week)
because ALT did not decrease to below 50%
pretreatment values, as scheduled in the study
TABLE III Relation between interferon dose and response in patients from group B
Total No No Sustained
dose of Response response Relapse response
Interferon dose (MU) cases n (%) n (%/°) n (%/o) n (%)
Maintained at 1-5 MU 216 27 13 (48) 14 (52) 3 (11) 10 (37)
Increased to 3 MU 396 24 10 (42) 14 (58) 6 (25) 4 (17)
Increased to 5 MU 588 20 2 (10) 18 (90) 1 (5) 1 (5)
Total 71 25 (35) 46 (65) 10 (14) 15 (21)
protocol. Treatment was interrupted because
of development of side effects, including neu-
tropenia, thrombocytopenia, severe depression
or hyperthyroidism, in seven patients from
group A and in five from group B. Treatment
was interrupted for other reasons, such as sub-
jective intolerance, travelling abroad or traffic
accident in nine additional patients, four from
group A and five from group B. No patient
withdrawn from treatment was excluded from
the study.
Of 70 patients included in group A, 20
(29%) fulfilled the criteria for response defined
above and 50 (71%) did not (Table II).
Response was transient in 12 (17%) and sus-
tained in eight (12%). Corresponding figures
for the 71 patients in group B were: 25 (35%)
for response, 46 (66%) for no response, 10
(14%) for transient response, and 15 (21%) for
sustained response (Table III). Thus, there
was a trend for better response in patients
treated with lower dose of interferon but the
difference did not reach statistical significance.
Complete normalisation ofALT at the end of
treatment seemed inversely related to the
amount of interferon necessary to induce a
decrease of ALT below 50/o of the pretreat-
ment values. This was particularly evident in
group B, where the proportion of responders
seen among patients treated exclusively with
1.5 MU injections (total dose 216 MU) was
significantly greater than in patients who
required an increase in the amount of interferon
given per injection up to 5 MU (total dose 588
MU) to keep ALT low (48% v 1.0%; Fisher's
exact test, p=0005) (Table III). In group A
there was also a trend for better response among
patients treated with 1.5 MU injections only
(total dose of 396 MU) than in those requiring
treatmnent with 3 MU or 5 MU injections (total
dose 450 to 648 MU) (Table II).
The proportion of patients with sustained
response after interferon withdrawal was also
higher among patients treated with low inter-
feron dose. In group A, sustained response was
recorded in five of 17 patients (30%) in whom
interferon administration could be reduced to
1.5 MU per injection (total dose 396 MU) but
in only three of 36 (8%) who received greater
amounts of interferon (total dose 450 or 648
MU) (p=0*05, Fisher's exact test) (Table II).
In group B, sustained response was seen in 10
of 27 patients (370/o) treated exclusively with
1.5 MU injections (total dose 216 MU) and in
five of 44 (13%) treated with higher doses
(total dose 396 or 588 MU) (p=0 01, Fisher's
exact test) (Table III).
In contrast, relapse upon interferon with-
drawal seemed directly related to the amount
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TABLE IV Relation between nornalisation ofserum
alanine aminotransferase (ALT) early during treatment
and the type of response
Patients with normalALT
No of At 4 weeks At 8 weeks
cases n (%0) n (%)
Non-responders 96 3 (3)* 4 (4)
Responders 45 21 (47) 31 (69)
Sustained responders 23 13 (56) 18 (78)
Transient responders 22 8 (36) 13 (59)
*Non-responders v responders at 4 weeks: difference between
proportions=0435, 95% CI 0-286 to 0-585, p<0000; at 8
weeks: difference between proportions=0647, 95% CI 0-506
to 0-788, p<0000.
of interferon that was necessary to maintain
low ALT values during treatment. In group A,
relapse occurred in three of eight (37%)
patients who maintained response with 1-5
MU doses and in nine of 12 (75%) patients
who required 3 MU or 5 MU doses (Table II).
In group B, relapse occurred in three of 13
(23%) patients with normal ALT while treated
with 1-5 MU dose and in seven of 12 (58%)
who required three or five MU doses (Table
III). These differences were not statistically
significant. When responders from both groups
were pooled, however, it became apparent that
relapse occurred in six of 21 patients (29%)
who maintained response with 1.5 MU and in
16 of 24 patients (67%) who required higher
dose of interferon to maintain ALT at normal
values during treatment (Fisher's exact test,
p=0O01).
Rapid normalisation of ALT after the start
of treatment was associated with response.
Normalisation ofALT after four or eight weeks
of treatment was more frequent in responders
(47% and 69% respectively), particularly in
those with sustained response (56% and 78%),
than in non-responders (3% and 4%). These
differences were statistically significant. The
frequency of rapid normalisation of ALT in
sustained responders was somewhat greater
than in transient responders but the difference
was not statistically significant (Table IV).
Responders and non-responders were
compared to investigate factors associated with
response (Table V). Univariate analysis showed
that responders were significantly younger than
TABLE V Factors associated with response to interferon therapy*
Responders Non-responders p
(n=45) (n=96) DBM 95% CI Value
Age (y) 41-8 (14-6) 50-1 (11-3) 8-30 3-86 to 12-7 0.001
Sex NS
males n (/) 30 (66) 52 (54)
females n (%) 15 (33) 44 (46)
Presumed source of infection 0.009
blood transfusion n (%) 13 (29) 30 (31)
use of intravenous drugs
n (%) 8 (18) 3 (3)
unknown n (%) 24 (53) 63 (66)
Platelet count (X 106/1) 196 (60) 167 (53) 29 9-24 to 48-8 0.005
WBC count (X106/l) 6.5 (2.3) 5-7 (1-5) 0-8 0-16 to 1.44 0-025
AST (IU/l) 142 (89) 133 (63) NS
ALT (IU/l) 282 (198) 241 (143) NS
AST/ALT 0.55 (037) 0-60 (020) NS
yGT (IU/1) 56 (66) 73 (48) NS
Histology NS
CAH n (%) 27 (60) 44 (46)
CAH with bridging n (%) 13 (29) 38 (39)
CAH with cirrhosis n (%) 5 (11) 14 (15)
*Quantitative data are expressed as mean (SD). Responders includes patients with sustained or
transient response. DBM, difference between means for quantitative variables. WBC=white
blood cell, yGT=-y glutamyltranspeptidase, CAH=chronic active hepatitis.
non-responders. History of intravenous drug
abuse in the past was more common in respon-
ders. No significant differences in serum aspar-
tate aminotransferase (AST) nor ALT activity
were found but platelet and white
blood cell counts were significantly higher in
responders. The degree of histological severity
was similar in responders and non-responders.
Multivariate analysis showed that only age had
independent predictive value of response.
Univariate analysis of baseline features dis-
closed several differences between patients with
and without sustained response. Sustained
responders were younger and their platelet
count and AST/ALT ratio were higher than in
non-sustained responders. History of intra-
venous use of drugs was more frequent in sus-
tained responders. The degree of histological
severity was similar in both groups (Table VI).
Sustained response occurred, however, in 16 of
71 patients (23%) with preserved lobular archi-
tecture but in only seven of 70 (10%) with
changed lobular architecture by the presence of
bridging fibrosis or cirrhosis (difference be-
tween proportions 0. 125, 95% confidence inter-
vals 00054 to 0.245, p=0.04). Multivariate
analysis showed that only age was indepen-
dently associated with sustained response.
Fifty four patients recruited at a single
centre were screened for specific antibodies
against HCV genotypes 1, 2, and 3. Thirty two
(59%) reacted for type 1, one (2%) for type 2,
five (9%) for type 3, five (9%) for genotypes 1,
and two and 11 (20%) did not react or gave
non-type specific reaction. The response to
interferon in these 54 patients did not differ
from that seen in the remaining 87 non-
screened patients recruited in other centres.
Table VII shows the relation between HCV
serotype and response to treatment. The pro-
portion of patients who showed sustained
response was significantly higher in patients
with HCV genotype 3 or with an unidentified
HCV genotype than in those infected with
genotype 1 (Fisher's exact test, p=0.0048 and
p=0*012 respectively). Of the 10 patients with
sustained response, seven were treated with
low dose interferon and four of them were
infected by serotype 3 of HCV. In patients
infected with HCV serotype 1, a sustained
response after treatment with 1.5 MU injec-
tions was achieved in one case only.
HCV-RNA was investigated in serum
samples taken before, during, and after treat-
ment in the 54 patients screened for HCV
serotypes. HCV-RNA was positive in all the
cases before treatment. The proportion of
patients in whom HCV-RNA became negative
was greater in responders than in non-
responders (Table VIII) although three
patients with sustained biochemical response
still had detectable HCV-RNA in serum by
nested polymerase chain reaction six months
after completion of treatment. However,
HCV-RNA became negative when these
patients were re-tested one year later.
The rate of negative values of HCV-RNA
seen after 12 weeks of treatment, at the end of
treatment, and at the end of follow up in
groups A and B was similar.
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TABLE VI Factors associated with sustained response to interferon therapy*
Sustained
responders Others p
(n=23) (n=118) DBM 95% CI Value
Age (y) 37-5(16-2) 49.5 (11-4) 12 6-46 to 17-5 0-002
Sex NS
males n (O/o) 14 (61) 68 (58)
females n (/) 9 (39) 50 (42)
Source of infection 0-021
blood transfusion n (O/o) 7 (30) 36 (31)
use of intravenous drugs
n (%) 5 (22) 6 (5)
unknown n (%) 11 (48) 76 (64)
Platelet count (X 106/) 203 (72) 171 (53) NS
WBC count (X106/l) 6-8 (2.9) 5-8 (1.8) 1 0-092 to 1.91 0-042
AST (IU/A) 147 (101) 134 (65) NS
ALT (IUI1) 319 (235) 242 (144) NS
AST/ALT 0-46 (0.09) 0-61 (0.28) 1-50 0.033 to 0-267 0.000
yGT (IU/l) 51 (41) 71 (57) NS
Histology NS
CAH n (O/o) 16 (70) 55 (47)
CAH with bridging n (%) 5 (22) 46 (39)
CAH with cirrhosis n (°/°) 2 (8) 17 (14)
*Quantitative data are expressed as mean (SD). Abbreviations as in Table V.
Discussion
The potential value of a interferon therapy for
the treatment of chronic non-A, non-B
hepatitis was recognised in 1986, several years
before the identification of HCV as the agent
responsible for this disease.27 To assess the
effectiveness of this treatment several con-
trolled trials were set up and a recent meta
analysis of these studies showed that a inter-
feron can induce remission of the disease in
about one half of treated patients although one
half of responders will relapse when the treat-
ment is stopped.28
In this study only 22 of 141 patients (1 5.6%)
had a sustained response. This low proportion
of responders is possibly due to patient selec-
tion because this study did not include patients
with a low index of histological activity or
chronic persistent hepatitis, who are believed
to respond better to interferon.29 30 In fact,
about one half of the patients selected for
inclusion had either cirrhosis or chronic active
hepatitis with bridging fibrosis and distorted
lobular architecture, which are factors associ-
ated with a poor response to interferon
therapy.29 31 32
Previous studies have suggested that, beside
these histopathological features, the response to
a interferon therapy may also be related to other
circumstances. Among host related factors, old
age,173334 long duration of the disease,3235
excessive body weight,3035 increased y gluta-
myltranspeptidadse,34 36 and iron overload33
have all been associated with diminished
response to interferon. Recently, factors directly
related to the causative agent, such as HCV
genotype37 38 or the amount of HCV-RNA
TABLE VII Relation between HCVserotype and the type
of response to interferon therapy
Type of response
No of Sustained Transient Absent
HCVserotype cases n (°/°) n (%o) n (%)
Type 1 32 4 (12) 7 (22) 21 (66)
Type2 1 0 0 1(100)
Type 3 5 4 (80) 0 1 (20)
Type 1+2 5 1 (20) 1 (20) 3 (60)
Not identified 11 1 (9) 4 (36) 6 (55)
Total 54 10 (19) 12 (22) 32 (59)
detected in serum1039 have also emerged as
important determinants of response.
The dose of interferon and the duration of
treatment can also influence the effectiveness
of the treatment. The probability of perma-
nent response seems greater if treatment is
given for at least 12 months4041 and a high
rate of sustained response in patients treated
for 60 weeks has recently been reported.42
The influence on response of the dose of
interferon is more controversial because the
results of studies showing that low dose is less
effective than high dose therapy16-18 do not
agree with other findings.'9 2041 To evaluate
the influence of the dose administered on the
final result of the treatment is an important
issue because a interferon is expensive and
often produces undesirable side effects, which
are dose related.
The main objective of this study was to
compare the effectiveness of two different
schedules of a interferon therapy given for 48
weeks. To this purpose, a large group of
patients with chronic active hepatitis C were
randomised to receive a interferon at increas-
ing or decreasing doses, starting from 1.5 MU
or 5 MU per injection respectively, according
to response. In contrast with other studies
aimed at comparing fixed doses of interferon,
the design of this trial permitted the adminis-
tration of increasing amounts of interferon in
those patients who failed to respond to lower
doses, according to a strategy that may be
effective in some patients.43
There were no differences in the rate of
response seen in patients treated with low,
increasing dose in comparison with those
treated with high, decreasing dose. In fact, the
proportion of patients who responded, either
transiently or permanently, was slightly
greater in patients who started treatment with
a low dose of interferon. As patients from
both groups were comparable, it may be sug-
gested that the effectiveness of the two thera-
peutic schedules evaluated in this study was
similar.
Beside the possible role of low dose inter-
feron therapy in chronic hepatitis C, other
aspects of this study deserve further comment.
Firstly, about two thirds of the patients who
developed a sustained response were able to
respond or to maintain ALT, or both below the
upper normal limit with 1.5 MU injections of
interferon. Secondly, sustained response was
strongly associated with a rapid fall ofALT, as
previously noted by others.44 In this study,
ALT became normal within the eight initial
weeks of treatment in 78% of the patients who
developed later a sustained response, including
those who started treatment with low doses of
TABLE VIII Detectability ofHCV-RNA in serum before,
during, and after interferon therapy according to the type of
biochemical response
Sustained Transient Absent
(n=10) (n= 12) (n=32)
Before therapy n (%) 10 (100) 12 (100) 32 (100)
At week 12 of therapy n (%) 5 (50) 8 (67) 27 (84)
At the end of therapy n (%/o) 5 (50) 9 (75) 27 (84)
At the end of follow up n (%/o) 3 (30) 12 (100) 29 (91)
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interferon. In contrast, rapid normalisation of
ALT was very rare in non-responders from the
two study groups.
These findings suggest that some patients
with chronic HCV infection are very sensitive
to interferon whereas other patients are refrac-
tory to this treatment. Distinction between
these two categories has important implica-
tions. In this study the small number of
patients who presented a sustained response to
low dose interferon made difficult the identifi-
cation of the features that characterise sus-
tained responders. Comparison of sustained
responders, most of whom achieved response
with low dose treatment, with non-sustained
responders, showed that young age, obvious
parenteral exposure to infection, and particu-
larly hiptory of addiction to intravenous drugs
in the past, high AST/ALT ratio, and pre-
served lobular architecture were associated
with complete response. Each of these vari-
ables has been recognised as a marker of
favourable response in previous studies where
patients received higher doses of interferon.30
In this study, however, logistic regression
analysis showed that only young age was
independently related to good response.
The influence of virological factors on the
response to treatment was analysed in more
than one third of the patients by testing for
HCV serotype and serum HCV-RNA.
Sustained response, even to low dose of inter-
feron, seemed associated with infection with
HCV serotype 3 whereas most patients
infected with HCV serotype 1 did not respond
or relapsed. These findings are in agreement
with recent observations from other large
serological surveys of patients with chronic
hepatitis C treated with different interferon
schedules.45-47 In these studies it has been
shown that aL interferon therapy is less effective
in patients with chronic hepatitis caused by
serotype 1 HCV than in patients infected by
other HCV serotypes.
There is increasing evidence that a low level
of viraemia is associated with longterm
response to interferon therapy in chronic
hepatitis C.10 39 48 Unfortunately, serum
HCV-RNA was not assessed because properly
processed and stored serum samples49
obtained at baseline were not available from
many patients. We have recently reported,
however, a good correlation between low
HCV-RNA serum concentration and a satis-
factory response to interferon in a large series
of patients from our hospital who otherwise
presented similar features to those included in
this study.50 Therefore, the presence of low
levels of viraemia in sustained responders from
the present series is likely.
As noted previously,'9 serum HCV-RNA
sequences were detected by nested polymerase
chain reaction despite sustained biochemical
remission in three of 10 patients. Although
these subjects cleared HCV-RNA when tested
one year later, the meaning and the prognostic
implications of the presence of HCV-RNA in
patients undergoing normalisation of ALT
under interferon therapy is currently uncer-
tain.
In summary, administration of 1-5 MU of ox
interferon three times a week for 48 weeks was
sufficient to induce sustained biochemical
remission in about 15% of patients with
chronic active hepatitis C in an area where
genotype 1 is highly prevalent. Response to
such a low dose of interferon can be expected
in young patients infected with HCV genotype
3 and, possibly, low level of viraemia.
Sustained response was heralded by rapid nor-
malisation of ALT. Increasing the dose of
interferon induced response in some patients
who did not respond rapidly to low doses but
most of them relapsed upon interferon with-
drawal. Initial treatment with 5 MU injections
followed by tapered doses in responding
patients did not increase the efficiency of treat-
ment with 1X5 MU initial doses. Failure of aL
interferon therapy is likely in patients with
chronic active hepatitis C who do not respond
rapidly to low dose ax interferon therapy. In
these patients, treatments other than at inter-
feron given alone must be prospectively inves-
tigated. As relapse may still occur in patients
responding to 48 week low dose therapy, treat-
ment for longer periods of time deserves
furhier evaluation.
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